Market Research Report
Global Breast Cancer Drugs Market - 2019-2026
|Published by||DataM Intelligence||Product code||812778|
Delivery time: 2 business days
|Global Breast Cancer Drugs Market - 2019-2026|
|Published: Pre-Order||Content info:||
Global Breast Cancer Drugs Market Overview
Breast cancer drugs are majorly divided into chemotherapy, hormone therapy, and targeted biological therapy. Chemotherapy is a systemic drug treatment intended to stop cancer cells from dividing and growing. Chemotherapy is often associated with unpleasant side effects since it targets all rapidly growing cells, in addition to cancer cells. Targeted/biological therapies (or immune targeted therapies) focus on blocking the actions of certain normal body proteins that allow cancer cells to grow and divide. These treatments target cancer cells, lessening toxicity and reducing side effects.
The global breast cancer drugs market was worth $XX million in 2018 and is forecasted to reach $XX million by 2026, at a CAGR of XX% during the forecast period.
Increase in prevalence of breast cancer cases across the globe, the rapid surge in awareness of breast cancer among the disease population and increase in survival rate of breast cancer population are driving the global breast cancer drugs market during the forecast period.
According to the American Cancer Society in 2018, it is estimated that 266,120 new cases of invasive breast cancer will be diagnosed in women in unites states.
According to Breast Cancer organization in 2018, estimated that About 1 in 8 U.S. women (about 12%) will develop invasive breast cancer over the course of her lifetime.
Major factors hindering the global breast cancer drugs market during the forecast period are the side effects caused by the disease population post medication it includes early menopause, bleeding, diarrhea, and others, and high cost associated with the therapeutic treatment.
Global breast cancer drugs market is segmented by therapy type and distribution channel. By therapy type includes hormone therapy, chemotherapy, and targeted therapy, hormone therapy includes selective estrogen receptor modulator (SERM), Aromatase Inhibitors, Estrogen-receptor down-regulators (ERD), and luteinizing hormone-releasing hormone agents (LHRH). The chemotherapy segment includes adjuvant chemotherapy, neoadjuvant chemotherapy, and advanced breast cancer, and targeted therapy includes trastuzumab, trastuzumab, ado-trastuzumab emtansine, lapatinib, and neratinib. The distribution channel hospitals, ambulatory surgical centers, clinics, retail Pharmacies, and online pharmacies.
Targeted therapy dominate the global breast cancer drugs market during the forecast period due to its less side effects offered by the treatment compared to the conventional therapy and cost-effective nature. Targeted cancer therapies or drugs that block the growth and spread of cancer by interfering with specific molecules that involved in growth, progression and spread of cancer.
Global Breast Cancer Drugs Market - Geographical Analysis
The global breast cancer drugs market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.
North America dominates the global breast cancer drugs market owing to rise in prevalence of breast cancer, the presence of key players and a rapid surge in extensive usage of targeted therapies across the region and it is expected remain high during the forecast period.
Presence of developed healthcare infrastructure and increased spending by the diseased population for treatment and continuous ongoing research by key players & research organizations for the development of advanced or targeted drugs is additionally contributing to the growth in North America during the forecast period.
According to American Cancer society, surveillance and health services research in 2016, approximately 50% of breast cancer diseased population were given a combination of mastectomy, radiation therapy and chemotherapy as their treatment plan by doctors.
Global Breast Cancer Drugs Market - Competitive Analysis
Recent FDA and European Union ( EU) approvals for advanced or metastatic breast cancer and new product launches by regional players are driving the global Breast Cancer Drugs market during the forecast period.
In January 2019, Hetero launches generic breast cancer treatment drug under the brand name 'Hertab' with the strength of 250g in India.
In October 2018, Eli Lilly's CDK 4 and 6 inhibitor Verzenios has been approved by the European Union for the treatment of certain metastatic breast cancers.
In July 2018, Novartis received new U.S FDA approval for Kisqali® (ribociclib for women with hormone-receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
In February 2018, Eli Lilly & co received FDA approval for expanded usage of Verzenio breast cancer drug as an initial treatment for certain women with advanced or metastatic disease.
Major market players in the breast cancer drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, Abbvie, Inc, Eli Lilly and Company, Astrazeneca, Celgene Corporation, Biocon, Merck & Co, Inc, Janssen Global Services LLC, Genzyme Corporation, and others.